Search Results for "cancer"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for cancer. Results 301 to 310 of 599 total matches.

Vimseltinib (Romvimza) for Tenosynovial Giant Cell Tumor (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 14, 2025  (Issue 1726)
Interactions: Concurrent use of vimseltinib and drugs that are substrates of P-glycoprotein, breast cancer ...
Vimseltinib (Romvimza – Deciphera), an oral kinase inhibitor, has been approved by the FDA for treatment of symptomatic tenosynovial giant cell tumor in adults for whom surgical resection would cause worsening functional limitation or severe morbidity. The kinase inhibitor pexidartinib (Turalio) was approved for a similar indication in 2019.
Med Lett Drugs Ther. 2025 Apr 14;67(1726):e66-7   doi:10.58347/tml.2025.1726h |  Show IntroductionHide Introduction

Drugs for Common Eye Disorders

   
The Medical Letter on Drugs and Therapeutics • Dec 02, 2019  (Issue 1586)
was that lung cancers occurred more frequently in patients who received beta carotene than in those who did ...
This issue includes reviews of drugs for glaucoma, age-related macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis is reviewed in a separate issue.
Med Lett Drugs Ther. 2019 Dec 2;61(1586):187-94 |  Show IntroductionHide Introduction

Pentostatin and 2-Chlorodeoxyadenosine for Hairy-Cell Leukemia

   
The Medical Letter on Drugs and Therapeutics • Sep 18, 1992  (Issue 879)
(JB Johnston et al, J Natl Cancer Inst, 80:765, 1988; EH Kraut et al, J Clin Oncol, 7:168, 1989; AD ...
Pentostatin (2'-deoxycoformycin; DCF; - Parke-Davis), a purine analog, was recently approved by the US Food and Drug Administration (FDA) for treatment of hairy-cell leukemia resistant to interferon alfa (Intron A; Roferon-A). is a rare (500 cases/year in the USA) form of chronic lymphocytic leukemia. Acutely ill patients may respond rapidly to interferon, but the drug is rarely curative. Another purine analog, 2-chlorodeoxyadenosine (CdA; Leustatin - Ortho Biotech), may also be approved soon for treatment of hairy-cell leukemia (JD Piro, Blood, 79:843, 1992). Fludarabine (Fludara...
Med Lett Drugs Ther. 1992 Sep 18;34(879):89-90 |  Show IntroductionHide Introduction

Over-the-counter H2-Receptor Antagonists for Heartburn

   
The Medical Letter on Drugs and Therapeutics • Oct 27, 1995  (Issue 960)
such as gastric cancer (M Feldman, Arch Intern Med, 153:2415, 1993). DRUG INTERACTIONS — Cimetidine interacts ...
Patients may be asking their physicians about use of histamine H2-receptor antagonists for treatment and prevention of heartburn. Cimetidine and famotidine have recently been released for over-the-counter sale and are being heavily advertised on television and in the print media.
Med Lett Drugs Ther. 1995 Oct 27;37(960):95-6 |  Show IntroductionHide Introduction

Rituximab for Non-Hodgkins Lymphoma

   
The Medical Letter on Drugs and Therapeutics • Jun 19, 1998  (Issue 1029)
, Cancer Biother Radiopharmaceuticals, 12:177, 1997). PHARMACOKINETICS — The half-life of rituximab ...
Rituximab (Rituxan - IDEC Pharmaceutical/Genentech), a monoclonal antibody, has been approved by the FDA for treatment of low-grade B-cell non-Hodgkin's lymphoma. Most low-grade lymphomas are B-cell lymphomas.
Med Lett Drugs Ther. 1998 Jun 19;40(1029):65-6 |  Show IntroductionHide Introduction

A New Conjugated Estrogen

   
The Medical Letter on Drugs and Therapeutics • Jul 30, 1999  (Issue 1058)
or uterine cancer, women with undiagnosed vaginal bleeding, active thrombophlebitis or thromboembolic ...
A new synthetic conjugated estrogen product (Cenestin - Duramed) was recently approved by the US Food and Drug Administration for treatment of vasomotor symptoms due to estrogen deficiency.
Med Lett Drugs Ther. 1999 Jul 30;41(1058):67-70 |  Show IntroductionHide Introduction

Carfilzomib (Kyprolis) for Multiple Myeloma

   
The Medical Letter on Drugs and Therapeutics • Dec 24, 2012  (Issue 1406)
bortezomib resistance. J Natl Cancer Inst 2011; 103:1007. 4. SD Demo et al. Antitumor activity of PR-171 ...
The FDA has approved carfilzomib (Kyprolis – Onyx), a proteasome inhibitor, for intravenous treatment of refractory multiple myeloma. Bortezomib (Velcade) was the first proteasome inhibitor to be approved for this indication.
Med Lett Drugs Ther. 2012 Dec 24;54(1406):103-4 |  Show IntroductionHide Introduction

In Brief: Dabrafenib (Tafinlar) and Trametinib (Mekinist) for Glioma (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023  (Issue 1674)
and involvement of lymph nodes following complete resection ▶ Metastatic non-small cell lung cancer (NSCLC ...
The oral kinase inhibitors dabrafenib (Tafinlar – GSK) and trametinib (Mekinist – Novartis) have been approved by the FDA for use together for a sixth indication: treatment of low-grade glioma (LGG) with a BRAF V600E mutation in patients ≥1 years old who require systemic therapy. This combination is the first systemic therapy to be approved in the US for first-line treatment of LGG with a BRAF V600E mutation in pediatric patients. The FDA also approved new oral formulations of both drugs for patients who are unable to swallow dabrafenib capsules or trametinib...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e75-6   doi:10.58347/tml.2023.1674i |  Show IntroductionHide Introduction

In Brief: Azmiro — A Single-Dose Injectable Formulation of Testosterone Cypionate

   
The Medical Letter on Drugs and Therapeutics • Mar 17, 2025  (Issue 1724)
(PSA) levels; whether it increases the risk of prostate cancer is unclear.3 Like other testosterone ...
The FDA has approved Azmiro (Azurity), the first injectable formulation of testosterone cypionate to become available in single-dose vials and prefilled syringes for treatment of males with conditions associated with a deficiency or absence of endogenous testosterone. Injectable testosterone cypionate has been available in multidose vials (Depo-Testosterone, and generics) for many years. Testosterone enanthate (Xyosted) is available in prefilled autoinjectors for use in adult men. No testosterone products are approved for treatment of low testosterone levels due solely to aging. All...
Med Lett Drugs Ther. 2025 Mar 17;67(1724):44-5   doi:10.58347/tml.2025.1724b |  Show IntroductionHide Introduction

Oral Oxymorphone (Opana)

   
The Medical Letter on Drugs and Therapeutics • Jan 01, 2007  (Issue 1251)
in relieving osteoarthritis and chronic low back pain, and was effective in relieving cancer pain in patients ...
Oxymorphone hydrochloride, a semi-synthetic opioid agonist, has been available for many years in the US as Numorphan (Endo) for parenteral use and as a rectal suppository. Now it has been approved by the FDA for oral administration as an immediate-release (IR) tablet (Opana) for treatment of moderate to severe acute pain, and as an extended-release tablet (Opana ER) for treatment of moderate to severe pain in patients requiring continuous opioid treatment for an extended period of time.
Med Lett Drugs Ther. 2007 Jan 1;49(1251):3-4 |  Show IntroductionHide Introduction